Acumen Pharmaceuticals, Inc. (ABOS) stock

ABOSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 26, 2026Score 2/30

$0.21−0.00 (-1.83%)

Close on Nov 13, 2026Market cap $15.48MP/E –Yield –

Acumen Pharmaceuticals gross margin

Gross margin is gross profit as a percentage of revenue.

Acumen Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?